FDA+ roundup: BsUFA III ready for showtime, court tells FDA to re-work compounding plan, new guidance updates and more
The FDA has now spelled out what exactly will be included in the third iteration of Biosimilar User Fee Act (BsUFA) from 2023 through 2027 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
